Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.
Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.
Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.
Severin Schwan, CEO of Roche Group, says the world was surprised by the "magnitude" of the Ebola outbreak.
Mergers have hit a level not seen since the financial crisis, and there is a way for investors to profit from the M&A frenzy—in one trade.
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
A breast cancer drug from Roche known as Perjeta helped patients live nearly 16 months longer compared with Herceptin and chemotherapy alone. CNBC's Meg Tirrell provides insight to the data.
Looking for new ideas as you put money to work in the stock market? Jim Cramer has plenty of them!
Language used to describe a recent acquisition, suggests to Jim Cramer there could be many more deals coming in this sector.
What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.
Stocks rose on Monday as investors welcomed M&A and looked to the European Central Bank for further monetary easing moves.
European shares closed higher on Monday following a key speech by Mario Draghi, the president of the European Central Bank.
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
U.S. stock-index futures rose on Monday, following European shares higher, as traders digested comments by the Fed's Yellen and the ECB's Draghi.
Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.
Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.